Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

被引：0

作者：

Eiji Shinozaki

Takayuki Yoshino

Kentaro Yamazaki

Kei Muro

Kensei Yamaguchi

Tomohiro Nishina

Satoshi Yuki

Kohei Shitara

Hideaki Bando

Sachiyo Mimaki

Chikako Nakai

Koutatsu Matsushima

Yutaka Suzuki

Kiwamu Akagi

Takeharu Yamanaka

Shogo Nomura

Satoshi Fujii

Hiroyasu Esumi

Masaya Sugiyama

Nao Nishida

Masashi Mizokami

Yasuhiro Koh

Yukiko Abe

Atsushi Ohtsu

Katsuya Tsuchihara

机构：

[1] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastrointestinal Oncology

[2] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology

[3] Shizuoka Cancer Center,Division of Gastrointestinal Oncology

[4] Aichi Cancer Center Hospital,Department of Clinical Oncology

[5] Saitama Cancer Center,Department of Gastroenterology

[6] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology

[7] Hokkaido University Hospital,Department of Gastroenterology and Hepatology

[8] Exploratory Oncology Research and Clinical Trial Center,Division of Translational Genomics

[9] National Cancer Center,Department of Computational Biology

[10] G&G Science Co. Ltd.,Division of Molecular Diagnosis and Cancer Prevention

[11] Graduate School of Frontier Sciences,Department of Biostatistics

[12] The University of Tokyo,Biostatistics Division

[13] Saitama Cancer Center,Division of Pathology

[14] National Cancer Center,Third Department of Internal Medicine

[15] Center for Research and Administration and Support,undefined

[16] National Cancer Center,undefined

[17] Exploratory Oncology Research & Clinical Trial Center,undefined

[18] National Cancer Center,undefined

[19] Research Institute for Biomedical Sciences,undefined

[20] Tokyo University of Science,undefined

[21] Genome Medical Science Project,undefined

[22] Research Center for Hepatitis and Immunology,undefined

[23] National Center for Global Health and Medicine,undefined

[24] Wakayama Medical University,undefined

[25] Exploratory Oncology Research & Clinical Trial Center,undefined

[26] National Cancer Center,undefined

[27] Kashiwa,undefined

[28] 20Present address: Department of Gastrointestinal Oncology,undefined

[29] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined

[30] Tokyo,undefined

[31] Japan.,undefined

[32] 21Present address: Department of Biostatistics,undefined

[33] Yokohama City University School of Medicine,undefined

[34] Yokohama,undefined

[35] Japan.,undefined

来源：

British Journal of Cancer | 2017年 / 117卷

关键词：

mutation; mutation; mutation; metastatic colorectal cancer; anti-epidermal growth factor receptor monoclonal antibody;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1450 / 1458

页数：8

共 462 条

[1]

Amado RG(2008)Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[2]

Wolf M(2012)Regulation of MEK/ERK pathway output by subcellular localization of B-Raf Biochem Soc Trans 40 67-72

[3]

Peeters M(2017)Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials Ann Oncol 28 1713-1729

[4]

Van Cutsem E(2014)Detection of circulating tumour DNA in early- and late-stage human malignancies Sci Transl Med 6 224ra24-1868

[5]

Siena S(2017)Primary tumour sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies Ann Oncol 28 1862-1414

[6]

Freeman DJ(2015)Location of colon cancer (right-sided Eur J Cancer 51 1405-1761

[7]

Juan T(2014) left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 Ann Oncol 25 1756-2097

[8]

Sikorski R(2015)Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial Ann Oncol 26 2092-954

[9]

Suggs S(2002)BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis Nature 417 949-762

[10]

Radinsky R(2010)Mutations of the BRAF gene in human cancer Lancet Oncol 11 753-1034

← 1 2 3 4 5 6 7 8 9 10 →